BlackRock Discloses 11.56% Voting Stake in QIAGEN

The latest update is out from Qiagen ( (QGEN) ).

BlackRock, Inc. has notified the Dutch Authority for the Financial Markets of a substantial holding in QIAGEN N.V., triggering a disclosure of voting rights under German securities law. Through a mix of ordinary shares and contracts for difference held via multiple subsidiaries, BlackRock now controls 10.41% of QIAGEN’s capital interest and 11.56% of its voting rights, underscoring a significant institutional stake in the diagnostics group.

The positions are largely held indirectly and include both real and potential voting rights, reflecting a combination of physical shareholdings and derivative exposures. While QIAGEN stresses it is not responsible for the accuracy of the AFM data, the filing highlights continued interest from major global asset manager BlackRock, which may influence shareholder dynamics and governance at the Venlo-based company.

The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

QIAGEN N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on several European exchanges as well as the NYSE and Swiss venues, giving it broad access to international capital markets.

Average Trading Volume: 2,172,951

Technical Sentiment Signal: Strong Buy

Current Market Cap: $9.85B

Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.